Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nona-L-arginine, also known as (Arg)9, nonaarginine, or polyarginine, is a synthetic cationic cell penetrating peptide (CPP) composed of nine L-arginine residues. It is primarily used as a cargo delivery system to facilitate the transport of various molecules—including proteins, peptides, and nucleic acids—across cellular membranes for research and potential therapeutic applications. Unlike some CPPs that directly traverse lipid bilayers, nona-L-arginine induces membrane multilamellarity and fusion to enter cells passively. This property makes it valuable in drug delivery systems and gene therapy research. Nona-L-arginine has also been investigated in clinical trials for its use in vascular grafts. Its mechanism involves modulating cellular uptake processes rather than targeting specific receptors or enzymes[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nona-l-arginine.